secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K/A
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001193125-25-319170
Event type: m_and_a
Sentiment:  negative
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind pro forma shows $36.1M net loss for H1 2025 post-scPharma acquisition
------------------------------------------------------------------------------

- Acquired scPharma for $5.35/share cash plus CVR (up to $1.00/share); total consideration $396.4M cash.
- Pro forma combined net loss of $36.1M for six months ended June 30, 2025 vs. MannKind standalone net income of $13.8M.
- Pro forma combined net loss of $96.9M for year ended Dec 31, 2024 (MannKind $27.6M income, scPharma $85.1M loss).
- Acquisition financed via $325M term loan (initial $75M, DDTL $75M, incremental $175M) at SOFR + 4.75% margin.
- Pro forma total assets $765.8M, total liabilities $832.6M, stockholders' deficit $66.8M as of June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000119312525319170/0001193125-25-319170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000119312525319170/mnkd-20251007.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-319170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer